
Two more novel therapies are quickly following the first approval in 2 decades for ALS.
Two more novel therapies are quickly following the first approval in 2 decades for ALS.
A genetic mutation suspected to be associated with amyotrophic lateral sclerosis risk has been confirmed through a large-scale research effort.
Serum testing for NMDAR and other autoantibodies is fraught with pitfalls, and careful clinical consideration is important.